RHBC
BEAM icon

R.H. Bluestein & Co’s Beam Therapeutics BEAM Stock Holding History

R.H. Bluestein & Co’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-2,000
Closed -$257K – 424
2021
Q2 		$257K Buy
+2,000
New +$159K 0.01% 358

Other funds holding BEAM

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

R.H. Bluestein & Co's BEAM Position: Q3 2021 in Review

R.H. Bluestein & Co sold out of Beam Therapeutics (BEAM) in Q3 2021, closing a stake of 2,000 shares — an estimated $257K sold.

R.H. Bluestein & Co first reported a position in BEAM in Q2 2021 and held it in 1 quarter. The position peaked at $257K in Q2 2021. 231 funds tracked by Wall St. Rank hold BEAM as of Q3 2021.

  • R.H. Bluestein & Co reported no remaining Beam Therapeutics position as of Q3 2021 after selling out during the quarter.
  • R.H. Bluestein & Co sold 2,000 Beam Therapeutics shares in Q3 2021, an estimated $257K.
  • R.H. Bluestein & Co first reported a position in Beam Therapeutics in Q2 2021 and held it in 1 quarter.
  • R.H. Bluestein & Co's Beam Therapeutics position peaked at $257K in Q2 2021.
  • 231 funds tracked by Wall St. Rank held Beam Therapeutics as of Q3 2021.

Based on R.H. Bluestein & Co's 13F filing for Q3 2021, filed 12 Nov 2021.